NAD Controls Pancreatic Beta-Cell Life, Death, and Regeneration
A landmark review reveals how NAD sits at the center of insulin secretion, beta-cell death, and regeneration — with major implications for diabetes and aging.
Resumen
This Japanese review article synthesizes decades of research from the Okamoto Laboratory at Tohoku University, showing that NAD is far more than a metabolic coenzyme in pancreatic beta-cells. CD38 uses NAD to produce cyclic ADP-ribose, which triggers calcium signaling and insulin secretion. Meanwhile, DNA damage activates PARP, which consumes NAD and causes beta-cell death. Crucially, when PARP activity is inhibited, it switches roles to act as a transcription factor, boosting expression of the regeneration factor RegI and driving beta-cell renewal. These interconnected pathways place NAD at the nexus of beta-cell function, death, and regeneration, with clear relevance to diabetes treatment strategies and the broader biology of aging.
Resumen detallado
NAD (nicotinamide adenine dinucleotide) is well known as an essential coenzyme in cellular metabolism, but this comprehensive review argues that its role as a substrate for key signaling proteins makes it equally critical to the life and death of pancreatic beta-cells — and potentially to aging itself.
The review centers on research from Professor Hiroshi Okamoto's laboratory at Tohoku University. One major finding is that CD38, a multifunctional enzyme, uses NAD as a substrate to synthesize cyclic ADP-ribose (cADPR). cADPR then elevates cytoplasmic calcium ion concentrations, directly stimulating insulin secretion from beta-cells. This positions NAD as a direct upstream regulator of glucose-stimulated insulin release.
On the destructive side, DNA damage in beta-cells activates poly(ADP-ribose) polymerase (PARP), which consumes large amounts of NAD to generate poly(ADP-ribose) chains. This NAD depletion leads to beta-cell necrosis — a mechanism implicated in type 1 diabetes models where beta-cells are destroyed by genotoxic stress.
Strikingly, when PARP activity is pharmacologically inhibited, it does not simply become inert. Instead, PARP transitions to function as a transcription factor, upregulating the expression of RegI, a known beta-cell regeneration and proliferation factor. This dual role of PARP — destroyer when active, regenerator when inhibited — is a remarkable mechanistic insight with therapeutic potential.
The review also connects these findings to the broader aging field, noting that NAD levels decline with age and that NAD-consuming enzymes like sirtuins, CD38, and PARP all compete for the same substrate pool. This makes NAD replenishment strategies potentially relevant not only for diabetes but for age-related beta-cell dysfunction. Caveats include that much of this work predates modern genetic tools and may rely on older experimental models.
Hallazgos clave
- CD38 uses NAD to synthesize cyclic ADP-ribose, elevating calcium and triggering insulin secretion.
- DNA damage activates PARP, depleting intracellular NAD and causing pancreatic beta-cell necrosis.
- PARP inhibition switches its role to transcription factor, upregulating beta-cell regeneration factor RegI.
- NAD links beta-cell function, death, and regeneration in a single integrated biochemical network.
- CD38, PARP, and sirtuins all compete for NAD, connecting beta-cell biology to aging mechanisms.
Metodología
This is a narrative review article written in Japanese, summarizing decades of experimental research from the Okamoto Laboratory at Tohoku University. It synthesizes biochemical, cell biology, and pharmacological studies on NAD-dependent enzymes in pancreatic beta-cells. No new primary data are presented; conclusions are based on prior published work.
Limitaciones del estudio
This is a review article with no new experimental data, limiting direct assessment of evidence quality. Much of the foundational research cited predates modern genomic and single-cell tools, which may affect mechanistic precision. The article is published in Japanese, and translation nuances may affect interpretation for non-Japanese readers.
¿Te ha gustado este resumen?
Recibe la última investigación sobre longevidad en tu bandeja de entrada cada semana.
Introduce tu correo electrónico para suscribirte: